National Prevalence of Multidrug-Resistant Organisms
OCT 28, 2016 | CONTAGION EDITORIAL STAFF
Vikas Gupta, PharmD, BCPS, director of Clinical Strategy at Becton Dickinson, discusses his research on the national prevalence of multidrug-resistant organisms.
Interview Transcript (slightly modified for readability)
“We studied several organisms; we studied multidrug-resistant Enterobacteriaceae, multidrug-resistant Acinetobacter, multidrug-resistant Pseudomonas, [and] ESBL, or extended-spectrum β-lactamase-producing organisms as well. We studied these because, as many of you are familiar with the 2013 CDC Antibiotic Threat Report, these organisms were categorized as urgent or serious threats, and it’s one of the reasons why we really selected these organisms, to get an idea of how much is really out there in the overall healthcare setting.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
We break down our top HIV news stories of 2017. Did you read them all?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512